A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide
- Indications Connective tissue disorders; Dermatomyositis; Interstitial lung diseases; Polymyositis; Systemic scleroderma
- Focus Therapeutic Use
- Acronyms RECITAL
- 22 May 2024 Results assessing treatment response presented at the 120th International Conference of the American Thoracic Society
- 14 Nov 2022 Results of subgroup analysis of this trial presented at the ACR Convergence 2022
- 06 Oct 2021 Status changed from discontinued to completed.